CA3056712A1 - Synthesis of mcl-1 inhibitor - Google Patents
Synthesis of mcl-1 inhibitor Download PDFInfo
- Publication number
- CA3056712A1 CA3056712A1 CA3056712A CA3056712A CA3056712A1 CA 3056712 A1 CA3056712 A1 CA 3056712A1 CA 3056712 A CA3056712 A CA 3056712A CA 3056712 A CA3056712 A CA 3056712A CA 3056712 A1 CA3056712 A1 CA 3056712A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- mol
- pyrazol
- solvent
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
- C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/72—Hydrazones
- C07C251/74—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C251/76—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Lubricants (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762479493P | 2017-03-31 | 2017-03-31 | |
| US62/479,493 | 2017-03-31 | ||
| PCT/EP2018/058056 WO2018178227A1 (en) | 2017-03-31 | 2018-03-29 | Synthesis of mcl-1 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3056712A1 true CA3056712A1 (en) | 2018-10-04 |
Family
ID=61827753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3056712A Pending CA3056712A1 (en) | 2017-03-31 | 2018-03-29 | Synthesis of mcl-1 inhibitor |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11149024B2 (https=) |
| EP (1) | EP3601230B1 (https=) |
| JP (1) | JP7032428B2 (https=) |
| KR (1) | KR102604876B1 (https=) |
| CN (1) | CN110536884B (https=) |
| AR (1) | AR111304A1 (https=) |
| AU (1) | AU2018244180B2 (https=) |
| CA (1) | CA3056712A1 (https=) |
| CO (1) | CO2019010035A2 (https=) |
| EA (1) | EA038226B1 (https=) |
| ES (1) | ES2909751T3 (https=) |
| IL (1) | IL269410B2 (https=) |
| MX (1) | MX387814B (https=) |
| TW (1) | TWI781996B (https=) |
| WO (1) | WO2018178227A1 (https=) |
| ZA (1) | ZA201905645B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3781570A4 (en) * | 2018-11-22 | 2021-06-02 | Ascentage Pharma (Suzhou) Co., Ltd. | MACROCYCLIC INDOLES SERVING AS MCL-1 INHIBITORS |
| WO2020151738A1 (en) * | 2019-01-23 | 2020-07-30 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic fused pyrrazoles as mcl-1 inhibitors |
| MA56505A (fr) | 2019-06-21 | 2022-04-27 | Janssen Pharmaceutica Nv | Inhibiteurs macrocycliques de mcl-1 |
| KR20220034136A (ko) | 2019-07-09 | 2022-03-17 | 얀센 파마슈티카 엔.브이. | Mcl-1 억제제로서의 거대환식 스피로사이클 유도체 |
| WO2021092053A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| EP4061819A1 (en) | 2019-11-21 | 2022-09-28 | Janssen Pharmaceutica NV | Macrocyclic indole derivatives as mcl-1 inhibitors |
| WO2021099580A1 (en) | 2019-11-21 | 2021-05-27 | Janssen Pharmaceutica Nv | Macrocyclic sulfonyl derivatives as mcl-1 inhibitors |
| EP4107161A1 (en) | 2020-02-21 | 2022-12-28 | Janssen Pharmaceutica NV | Macrocyclic indole derivatives as inhibitors of mcl-1 |
| JP2023526985A (ja) | 2020-05-29 | 2023-06-26 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１の阻害剤としての大環状７－ピラゾール－５－イル－インドール誘導体 |
| WO2021255258A1 (en) | 2020-06-19 | 2021-12-23 | Janssen Pharmaceutica Nv | N-linked macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
| BR112022025674A2 (pt) | 2020-06-19 | 2023-01-17 | Janssen Pharmaceutica Nv | Derivados de 7-(pirazol-5-il)-indol macrocíclico n-ligado como inibidores de mcl-1 |
| BR112023000212A2 (pt) | 2020-07-08 | 2023-01-31 | Janssen Pharmaceutica Nv | Éter macrocíclico contendo derivados de indol como inibidores de mcl-1 |
| WO2022032284A1 (en) * | 2020-08-07 | 2022-02-10 | Zeno Management, Inc. | Macrocyclic compounds |
| CA3200758A1 (en) | 2020-12-17 | 2022-06-23 | Janssen Pharmaceutica Nv | Branched macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
| CN116848126A (zh) | 2021-02-12 | 2023-10-03 | 詹森药业有限公司 | 大环1,3-桥联的6-氯-7-吡唑-4-基-1h-吲哚-2-羧酸酯和6-氯-7-嘧啶-5-基-1h-吲哚-2-羧酸酯衍生物作为mcl-1抑制剂用于治疗癌症 |
| TWI910028B (zh) | 2021-06-11 | 2025-12-21 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
| US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2915811A1 (en) * | 2014-03-04 | 2015-09-09 | Centre Régional de Lutte contre le Cancer - Centre François Baclesse | MCL-1 modulating compounds for cancer treatment |
| US9949965B2 (en) * | 2014-10-17 | 2018-04-24 | Vanderbilt University | Tricyclic indole Mcl-1 inhibitors and uses thereof |
| CN105061315B (zh) * | 2015-08-06 | 2017-10-24 | 大连理工大学 | 一类1,5‑二苯基吡唑‑3‑羧酸类化合物及其应用 |
| ES2791319T3 (es) * | 2016-04-22 | 2020-11-03 | Astrazeneca Ab | Inhibidores de MCL1 macrocíclicos para tratar el cáncer |
| CN106478606B (zh) * | 2016-09-21 | 2019-05-10 | 沈阳药科大学 | N-取代吲哚类衍生物及其应用 |
-
2018
- 2018-03-26 TW TW107110205A patent/TWI781996B/zh active
- 2018-03-28 AR ARP180100757A patent/AR111304A1/es unknown
- 2018-03-29 US US16/497,919 patent/US11149024B2/en active Active
- 2018-03-29 AU AU2018244180A patent/AU2018244180B2/en active Active
- 2018-03-29 WO PCT/EP2018/058056 patent/WO2018178227A1/en not_active Ceased
- 2018-03-29 ES ES18714249T patent/ES2909751T3/es active Active
- 2018-03-29 MX MX2019011468A patent/MX387814B/es unknown
- 2018-03-29 CA CA3056712A patent/CA3056712A1/en active Pending
- 2018-03-29 CN CN201880021146.0A patent/CN110536884B/zh active Active
- 2018-03-29 EP EP18714249.2A patent/EP3601230B1/en active Active
- 2018-03-29 JP JP2019552891A patent/JP7032428B2/ja active Active
- 2018-03-29 EA EA201992235A patent/EA038226B1/ru unknown
- 2018-03-29 KR KR1020197031979A patent/KR102604876B1/ko active Active
-
2019
- 2019-08-27 ZA ZA2019/05645A patent/ZA201905645B/en unknown
- 2019-09-16 CO CONC2019/0010035A patent/CO2019010035A2/es unknown
- 2019-09-17 IL IL269410A patent/IL269410B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI781996B (zh) | 2022-11-01 |
| JP2020515557A (ja) | 2020-05-28 |
| CN110536884A (zh) | 2019-12-03 |
| IL269410B2 (en) | 2023-03-01 |
| KR102604876B1 (ko) | 2023-11-22 |
| BR112019019686A2 (pt) | 2020-04-14 |
| JP7032428B2 (ja) | 2022-03-08 |
| US20210122735A1 (en) | 2021-04-29 |
| US11149024B2 (en) | 2021-10-19 |
| MX2019011468A (es) | 2019-11-01 |
| IL269410B (en) | 2022-11-01 |
| AU2018244180B2 (en) | 2021-03-04 |
| WO2018178227A1 (en) | 2018-10-04 |
| ES2909751T3 (es) | 2022-05-10 |
| ZA201905645B (en) | 2020-05-27 |
| EP3601230B1 (en) | 2022-01-26 |
| KR20190136039A (ko) | 2019-12-09 |
| MX387814B (es) | 2025-03-04 |
| EA038226B1 (ru) | 2021-07-27 |
| AU2018244180A1 (en) | 2019-11-07 |
| CN110536884B (zh) | 2023-05-02 |
| TW201902868A (zh) | 2019-01-16 |
| EA201992235A1 (ru) | 2020-02-10 |
| IL269410A (en) | 2019-11-28 |
| AR111304A1 (es) | 2019-06-26 |
| CO2019010035A2 (es) | 2019-09-30 |
| EP3601230A1 (en) | 2020-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018244180B2 (en) | Synthesis of Mcl-1 inhibitor | |
| JP2021035947A (ja) | ブルトンチロシンキナーゼ阻害剤の合成 | |
| TWI697494B (zh) | 科帕利普（ｃｏｐａｎｌｉｓｉｂ）及其二鹽酸鹽之合成 | |
| TW201625634A (zh) | 科帕利普（ｃｏｐａｎｌｉｓｉｂ）及其二鹽酸鹽之合成 | |
| WO2019141131A1 (zh) | 溴结构域抑制剂化合物及其用途 | |
| CN115703758B (zh) | 一类用作激酶抑制剂的化合物及其制备方法和用途 | |
| CN109942499B (zh) | 喹唑啉衍生物及其制备方法和应用 | |
| CN107162951B (zh) | 一种靛红-3-肟衍生物的制备方法 | |
| HK40022816A (en) | Synthesis of mcl-1 inhibitor | |
| HK40022816B (en) | Synthesis of mcl-1 inhibitor | |
| BR112019019686B1 (pt) | Compostos selecionados para síntese de inibidor de mcl-1 | |
| HK40013365A (en) | Synthesis of mcl-1 inhibitor | |
| HK40013365B (en) | Synthesis of mcl-1 inhibitor | |
| TW201625632A (zh) | Ｐｉ３ｋ抑制劑及其鹽之合成 | |
| CN112441970A (zh) | 一类2，5-二取代-3-氨基吡啶化合物及其制法和用途 | |
| KR20200092945A (ko) | 레날리도마이드의 결정형 | |
| CN121293155A (zh) | 用于达罗他胺的中间体的制备方法 | |
| CN118994108A (zh) | 一种lsd1抑制剂类化合物的晶型及其制备方法 | |
| CN119431319A (zh) | 环戊基并吡啶衍生物的制备方法 | |
| CN114787166A (zh) | 噻吩并[2,3-c]哒嗪-4(1H)-酮类化合物的晶型及其制备方法和应用 | |
| CN102491985A (zh) | 6-氨基-2，2-二甲基-2H-吡啶[3，2-b][1，4]恶嗪-3（4H）-酮的合成方法 | |
| HK1241883B (zh) | Copanlisib及其二盐酸盐的合成 | |
| HK1241883A1 (en) | Synthesis of copanlisib and its dihydrochloride salt | |
| WO2017162304A1 (en) | Crystalline form |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230306 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240909 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250113 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250314 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250314 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250314 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250417 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250417 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW Effective date: 20250512 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250528 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250529 |